IN DEPTH

Without a trace: can pharma reduce scarring?

Blood plasma production: OK for the UK?

Can pharma keep up with mental health?

Vaccines

Malaria vaccines through the ages

A novel malaria vaccine could be a major breakthrough against the disease

regulation

Tightening the rules on pharma M&A 

ingredients

The fishy business of shark squalene alternatives

Without a trace: can pharma reduce scarring?

Blood plasma production: OK for the UK?

Can pharma keep up with mental health?

02/24/2024 07:38:58
  • Home | Time for UK plasma to shine
  • In this issue
  • Contents
  • Datwyler
  • Labcorp
  • UPS Healthcare Company Insight
  • UPS Healthcare
  • Baxter
  • SHL Medical
  • Briefing
  • Industry news
  • The pharma industry briefing
  • Covid-19 executive briefing by GlobalData
  • Mimotopes Company Insight
  • Mimotopes
  • PerkinElmer
  • Comment
  • A new day for Alzheimer’s disease treatment
  • Covid-19 vaccine inequity: the debate over patent waivers intensifies
  • Covid-19 vaccines show efficacy in adolescents
  • International pharmacovigilance for biotechs: forming a strategy
  • Nipro
  • HOF Sonderanlagenbau
  • Myonex
  • In Depth
  • Malaria vaccines through the ages
  • Are competition authorities tightening the rules on pharma M&A?
  • The fishy business of shark squalene
  • Without a trace: can pharma reduce scarring?
  • Blood plasma production: OK for the UK?
  • When the drugs don’t work: can pharma keep up with mental health?
  • The Solubility Company - Company Insight
  • The Solubility company
  • Owen Mumford Company Insight
  • Owen Mumford
  • In Data
  • Deals analysis
  • The pharma industry key list
  • Global markets and indices
  • Macro-economic indicators
  • Macro-economic indicators (page 2)
  • Events
  • Next issue
06/18/2021 00:00:00